TLDR
- Shares of Xenon Pharmaceuticals rocketed 40% following positive Phase 3 X-TOLE2 data showing azetukalner achieved primary goals across both dosage levels.
- Patients receiving 25 mg experienced a 53.2% reduction in monthly focal onset seizures compared to baseline, versus just 10.4% with placebo.
- These findings exceeded the earlier Phase 2b X-TOLE trial, which demonstrated a 34.6% placebo-adjusted median reduction.
- More than half of participants (54.8%) on the 25 mg dosage achieved a minimum 50% decrease in seizure occurrence.
- The company intends to submit a New Drug Application (NDA) to the FDA during the third quarter of 2026.
Shares of Xenon Pharmaceuticals (XENE) exploded 40% higher Monday following the biotech’s announcement that azetukalner successfully achieved its primary goal in the Phase 3 X-TOLE2 trial for focal onset seizures. The better-than-anticipated outcome triggered a sharp rally when markets opened.
Xenon Pharmaceuticals Inc., XENE
The clinical study included 380 adult participants battling treatment-resistant epilepsy. These individuals had previously attempted a median of five different anti-seizure therapies yet continued suffering approximately 12.75 seizures monthly before entering the trial.
Patients taking the 25 mg azetukalner dose experienced a median reduction of -53.2% in monthly focal onset seizure frequency from their starting point. Meanwhile, those on placebo saw only a -10.4% decrease. This translates to a placebo-adjusted difference of -42.7%.
This figure carries significant weight. The company’s previous Phase 2b X-TOLE trial had delivered a placebo-adjusted median reduction of -34.6% with the 25 mg dosage. X-TOLE2’s performance substantially exceeded this benchmark.
The lower 15 mg dose also demonstrated efficacy, achieving a -34.5% median reduction versus placebo, although the 25 mg findings garnered primary focus.
Secondary Endpoints Also Hit
The study successfully achieved its crucial secondary objective. Among participants receiving 25 mg, 54.8% experienced at least a 50% decrease in monthly seizure frequency — the metric known as Responder Rate 50. This contrasted sharply with the placebo group’s 20.8%. The 15 mg cohort registered 37.6%.
Among 332 participants completing the double-blind phase, 322 transitioned into the open-label extension portion.
The drug’s safety record remained solid. Most frequently reported adverse effects included dizziness, headache, somnolence, and fatigue. Discontinuation rates due to adverse events stood at 14.5% for the 25 mg cohort, 4.8% for 15 mg, and 3.2% for placebo.
Xenon’s CEO Ian Mortimer stated the findings demonstrated “the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study,” per the company’s official statement.
What Comes Next
The company plans filing an NDA with the FDA for azetukalner in treating focal onset seizures during Q3 2026. Approval would mark the first KV7 potassium channel opener reaching market for epilepsy treatment.
Stifel’s analyst team suggested the outcome may prompt investors to increase their projected peak sales and market penetration forecasts for the therapy.
Azetukalner offers several practical benefits compared to current alternatives — including once-daily administration, no titration requirements, and minimal drug-drug interactions.
The X-TOLE2 findings will receive presentation during an oral session at the American Academy of Neurology (AAN) Annual Meeting this April.
Xenon is separately advancing azetukalner for depression treatment, though that development program wasn’t addressed in Monday’s update.
Shares traded approximately 40% higher Monday morning, with the surge attributed solely to the Phase 3 data release.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
